IMIBIO-SL CONICET, Facultad de Química, Bioquímica y Farmacia, Universidad Nacional de San Luis, San Luis, San Luis, Argentina.
Instituto de Biotecnología, Facultad de Ingeniería, Universidad Nacional de San Juan, San Juan, San Juan, Argentina.
Arch Pharm (Weinheim). 2024 Apr;357(4):e2300581. doi: 10.1002/ardp.202300581. Epub 2024 Jan 16.
This study aimed to evaluate the in silico and in vitro inhibitory effect of the combined use of galantamine (GAL) and donepezil (DON) against acetylcholinesterase and butyrylcholinesterase (BuChE) enzymes. In silico and in vitro cholinesterase analysis were carried out for GAL and DON alone and combined. Molecular modeling studies were carried out (docking analysis, molecular dynamics simulation, and quantum theory of atoms in molecules). Cholinesterase's inhibitory activities by modified Ellman's method and the drug combination effect using the Chou-Talalay method were assayed. GAL/DON combination showed the co-occupancy of the ligands in both enzymes through in silico studies. Regarding in vitro BuChE inhibition analyses, three of five combinations showed an interaction between GAL and DON at the threshold of additive affect (0.9 < CI < 1.1), with a tendency toward a synergistic effect for higher concentrations. This is the first report showing the efficacy of the GAL/DON combinations inhibiting BuChE, showing the importance of analyzing the behavior of different ligands when co-occupancy into the active site is possible. These combinations might be a possible therapy to improved efficacy, reduced doses, minor side effects, and high levels of the neurotransmitter in the synaptic space for Alzheimer's disease.
本研究旨在评估加兰他敏(GAL)和多奈哌齐(DON)联合使用对乙酰胆碱酯酶和丁酰胆碱酯酶(BuChE)的体外和体内抑制作用。对 GAL 和 DON 单独使用和联合使用进行了体外和体外胆碱酯酶分析。进行了分子建模研究(对接分析、分子动力学模拟和原子分子量子理论)。采用改良的 Ellman 法测定了胆碱酯酶的抑制活性,并采用 Chou-Talalay 法测定了药物联合作用。通过计算机模拟研究表明,GAL/DON 联合可使两种酶中的配体共同占据。关于体外 BuChE 抑制分析,五种组合中的三种在加和影响的阈值(0.9 < CI < 1.1)下表现出 GAL 和 DON 之间的相互作用,在较高浓度下表现出协同作用的趋势。这是第一个报告显示 GAL/DON 联合抑制 BuChE 的功效的报告,表明当配体共同占据活性位点时,分析不同配体的行为非常重要。这些组合可能是改善阿尔茨海默病患者神经递质在突触空间中的疗效、降低剂量、减少副作用和提高水平的有效方法。